Clinical Trial Update: An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis [Phase 4]

View source ↗

Summary

This is an open-label, multicenter long-term extension study of etanercept in ankylosing spondylitis (Phase 4), which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• ENBREL (etanercept)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Ankylosing Spondylitis | Phase 4 | Status: COMPLETED